Environmental biotechnology is the branch of biotechnology that addresses environmental problems, such as the removal of pollution, renewable energy generation or biomass production, by exploiting ...

Unveiled during the BioWave event at C-CAMP in Bangalore, the report presents a deep dive into India’s biotech funding landscape from 2020 to 2024. The report reveals that India’s biotech ...

Or, maybe, it's just a grey wolf with a few tweaks. American biotech company Colossal Biosciences made a surprise announcement Monday, claiming it had brought the dire wolf back from the dead ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

America must invest at least $15 billion over the next five years to support its domestic biotechnology sector if it doesn’t want to lose to China, warns a national security commission made up ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should ...

The U.S.-based biotechnology company is also known for its ambitious goal of bringing back the extinct woolly mammoth by 2028. This dire wolf pup is among the first of its species born in around ...

The biotech firm, known for its ambitious de-extinction projects, previously gained attention for its woolly mammoth revival efforts. While Colossal attracts significant funding and celebrity ...

Caitlin O'Kane is a New York City journalist who works on the CBS News social media team as a senior manager of content and production. She writes about a variety of topics and produces "The ...

A biotech company says it has bred three animals with key physical features of the dire wolf — a species that has been extinct for more than 12,000 years. Colossal Biosciences says it used novel ...

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., the report said. China is moving fast to ...

Legend Biotech has no tariff exposure and manufactures Carvykti entirely in the U.S. for both U.S. and EU markets. HC Wainwright maintains a $75 target, citing Carvykti’s strong efficacy and ...